Olanzapine counteracts stress-induced anxiety-like behavior in rats

Atypical antipsychotics, such as olanzapine, have been reported to display anxiolytic properties as shown in several preclinical and clinical studies. Furthermore, several experimental evidences have shown that olanzapine reduces fear and anxiety in activated anxiety-like behavior test such as Geller-Seifter test, ultrasonic vocalization test and stress-induced EtOH consumption. Here, we hypothesized that the anxiolytic action of olanzapine might be due to via an indirect activation of the γ-amino butyric acid (GABA)-ergic system through 3α-hydroxy-5α-pregnan-20-one [allopregnanolone (ALLO)], a potent neuroactive steroid that positively modulates the benzodiazepine-γ-aminobutyric acid type A (GABA_A)/benzodiazepine receptors complex. To address this question, we used a preclinical animal test to screen for novel anxiolytic compounds – the elevated plus-maze (EPM) – in basal condition and after 45 min restrain stress after acute or repeated (21 days) administration of olanzapine (0.5 mg/kg, i.p.). In this condition, we therefore study the effect of the 5-alpha-reductase inhibitor finasteride (FIN) (50 mg/kg) after co-administration with olanzapine. FIN is an inhibitor of steroidogenic enzymes which acts by inhibiting type II 5-alpha reductase, the enzyme that converts into 5-alpha-reduced metabolites like the GABA_A positive neuroactive steroid ALLO. Results showed an anxiolytic effect of the acute, but not of the chronic, treatment with olanzapine only in stressed rats. This anxiolytic effect was counteracted by the co-administration with FIN. These evidences suggest that the anxiolytic effects of olanzapine might be due to possible action of olanzapine on steroid function via activation of GABA system.     

VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders

We examined microvessel density (MVD) and immunohistochemical expression of vascular endothelial growth factor (VEGF) in the bone marrow biopsy specimens of 98 patients with Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders (CMPDs). There were significantly more MVD "hot spots" in chronic idiopathic myelofibrosis (CIMF; mean +/- SD, 25.6 +/- 6.3) and polycythemia vera (PV; 20.7 +/- 10.2) cases than in essential thrombocythemia (ET) cases (10.1 +/- 4.5) and normal control (NC) samples (7.5 +/- 3.6) (P < .05). Similar results were found using a semiquantitative method (P < .0001). A calculated VEGF index (VEGF(i)) was higher in CIMF (0.29 +/- 0.15) and PV (0.28 +/- 0.20) cases than in ET (0.12 +/- 0.05) and NC (0.08 +/- 0.04) cases (P < .0001). MVD and VEGF(i) were higher in the myelofibrotic phases of CIMF and PV. There was a direct correlation between VEGF(i) and MVD when considering the Ph- CMPDs together (r = 0.67; P < .001) and when considering PV (r = 0.79; P < .001) and CIMF (r = 0.40; P = .013) as individual entities. Our data could provide a rationale for directly targeting VEGF or endothelial cells in CIMF and PV.     

Genistein restores caveolin-1 and AT-1 receptor expression and vascular function in large vessels of ovariectomized hypertensive rats

OBJECTIVE: The soy-derived phytoestrogen genistein improves endothelial function in postmenopausal women and ovariectomized (OVX) normotensive rats. We hypothesized that genistein would improve vascular reactivity involving changes in endothelial nitric oxide synthase (NOS) expression and its regulatory proteins (caveolin and calmodulin), angiotensin II receptor, and/or oxidative status in OVX spontaneously hypertensive rats (SHRs). DESIGN: After ovariectomy or sham operation, 23-week-old female SHRs received either 17beta-estradiol (2 mg/kg/wk SC), genistein (10 mg/kg/d by gavage), or placebo. RESULTS: In OVX rats, final body weight was increased and uterus weight was decreased, and these values were reduced and increased, respectively, by 17beta-estradiol but unaffected by genistein. Acetylcholine-induced endothelium-dependent vasorelaxation was significantly blunted in aortas from OVX placebo SHRs. The contractions induced by the NOS inhibitor L-NAME and angiotensin II in OVX placebo were lower and higher, respectively, than in sham rats. Estradiol and genistein restored these functional changes. Aortic endothelial NOS and calmodulin-1 expression were unchanged, whereas caveolin-1 and angiotensin II receptor expression was increased in OVX rats. Estradiol and genistein treatment did not modify endothelial NOS, but normalized caveolin-1 and angiotensin II receptor and increased calmodulin-1 expression. Vascular superoxide production was increased in OVX placebo and normalized by both estradiol and genistein. CONCLUSIONS: Genistein prevented all cardiovascular changes induced by estrogen depletion in SHRs to a similar extent as estradiol but had no uterotrophic effect. The present findings may help to explain the potential benefits of genistein as a therapeutic agent for preventing menopausal vascular complications, especially in hypertensive women.     

A two-signal model for T cell trafficking

T-cell-receptor triggering and the delivery of co-stimulation are essential events leading to T cell expansion, differentiation and effector function. The influence that such signals exert on T cell migration during and following priming has been highlighted by recent reports. Moreover, induction of peripheral tolerance might act in part by affecting T cell migration. Here, we propose that the integration of co-stimulatory signals, which regulate the ability of primed T cells to access nonlymphoid tissue, and cognate recognition of the endothelium, which determines the selective recruitment of specific T cells, contribute to the anatomy of T cell-mediated immunity and tolerance. The implications for therapeutic strategies manipulating these signals are discussed.     

Efficacy of low-dose rituximab for mixed cryoglobulinemia

Rituximab at 375 mg/m(2) x 4 is effective for refractory HCV-related mixed cryoglobulinemia. We conducted a pilot study to assess the efficacy of a lower dosage, 250 mg/m(2) x 2. Six consecutive patients with mixed cryoglobulinemia were treated. All patients had severe or life-threatening disease manifestations, including necrotizing skin ulcers, renal disease, hyperviscosity or intestinal vasculitis. Four of five evaluable patients (excluding one early death) had >80% decrease of cryocrit and remission of vasculitis at the end of a 22- to 55-week (median 40) follow-up. The non-responder failed to respond to additional rituximab treatment, suggesting intrinsic resistance rather than insufficient dosage as the cause of treatment failure. No sustained increase of HCV viremia after rituximab was observed. Rituximab at 250 mg/m(2) x 2 may be as effective as at 375 mg/m(2) x 4 for treating mixed cryoglobulinemia. Larger studies are required to assess the efficacy of low-dose rituximab.     

Post silanization improves bond strength of translucent posts to flowable composite resins

The aim of the study is to evaluate the effect of post silanization on the microtensile bond strength (MTBS) of translucent fiber posts to seven flowable composite resins used as core material. Seventy fiber posts were employed. In half of the posts, silanization was performed with Monobond-S. A cylindrical plastic matrix was placed around the post and filled with different resins: UniFil Flow Experimental, UniFil Low Flow Plus Experimental, Venus Flow, Revolution Formula 2, Point 4 Flowable, X-Flow, and Wave mv. Five posts were bonded per group. After polymerization, two longitudinal cuts were made on two opposite sides of the post at its outermost periphery. Then, each specimen was serially sectioned, obtaining 30-35 beams with 1-mm(2) cross-sectional area. Each beam was tested in tension in an Instron machine at 0.5 mm/min. ANOVA and Student Newman Keuls tests were performed. The different resin composite materials and the post silanization procedure had a significant effect on MTBS. The application of a silane coupling agent increased MTBS of flowable composite resins to translucent posts. X-flow and Point 4 attained the highest MTBS regardless of the silane treatment.     

In vitro bioactivity and degradation of polycaprolactone composites containing silicate fillers

In spite of numerous publications on the potential use of combinations of polycaprolactone (PCL)/bioactive fillers for bone regeneration, little information exists on the assessment of solid, nonporous composites prepared via solventless routes and consisting of unmodified, slowly degrading homopolymer with relatively low amounts of reactive fillers such as bioglass or calcium silicate (CS). Thus, composites of PCL with commercial CS and a bioactive glass (BG45S5) at 30wt.% were produced by melt mixing in a twin screw extruder. Neat fillers, PCL and their composites were immersed in simulated body fluid (SBF) and phosphate buffer saline and tested for in vitro bioactivity and degradation, respectively, over a 4 month period. Testing methods included scanning electron microscopy with energy dispersive X-ray analysis, X-ray diffraction (XRD), elemental analysis and weight and pH changes before and after immersion. Experiments with neat fillers indicated fast growth of calcium phosphate minerals having different textures; they included clusters and globules of mineral precipitates as well as needle-shaped nanosized crystallites and possibly other calcium phosphate structures with varying Ca/P ratio. The bioactive glass composite initially showed fast growth of the precipitated minerals and partial surface coverage after 1 week, whereas in the CS composite, growth and surface coverage increased as a function of immersion time (over a period of 4 weeks) in the SBF solution. XRD results showed early appearance (1 week) of hydroxyapatite for both types of composites with differences attributed to different dissolution rates and different surface reactions of the fillers. Both fillers appeared to enhance the hydrolytic degradation of the matrix. Overall, the limited observed bioactivity of both composites within the test period may be related to the hydrophobicity of the matrix, insufficient ionic activity since SBF was not replenished and the relatively low content of the low surface areas fillers. Optimization of filler properties, such as surface/volume ratio, surface chemistry and size range, appears as a most important factor that would provide, at the required high filler volume fractions, a balance of melt processability and bioactivity.     

Oocyte cryopreservation: oocyte assessment and strategies for improving survival

Despite significant progress in cryopreservation of mammalian oocytes and embryos, many ofthe molecular and biochemical events that underlie this technology are poorly understood. In recent years, researchers have focused on obtaining viable oocytes that are developmentally competent. Even under the most favourable conditions, experimental approaches have achieved only limited success compared with fresh oocytes used in routine in vitro embryo production. Chilling injuries and toxic effects of the cryoprotectants are the major adverse consequences following cryoprocedures. To overcome these problems, different strategies have been developed for improving cryopreservation results. These strategies include reducing container volumes, increasing the thermal gradient, changing the cell surface/volume ratio, enhancing cryotolerance by supplementation with various additives or modifying the lipid composition of the oocyte membrane. In order to develop new strategies for reducing the various forms of stress associated with oocyte cryopreservation, it is fundamental to gain a better understanding of the major changes responsible for poor post-thaw survival. With this knowledge, we hope that oocyte cryostorage will become a fully reliable reproductive technique in the near future.